TY - JOUR
T1 - Determinants of pancreatic tropism in metastatic renal cell carcinoma
AU - Xu, Haitao
AU - Kapur, Payal
AU - Christie, Alana
AU - Nielsen, Aleksandra W.
AU - Perny, Averi
AU - Brandenburg, Olivia
AU - Small, Charlotte
AU - Miyata, Jeffrey
AU - Zhong, Hua
AU - Roberts, Courtney
AU - Elias, Roy
AU - Tcheuyap, Vanina
AU - Duarte, Cassandra
AU - van Bokhoven, Adrie
AU - Panian, Justine
AU - Li, Haoran
AU - Collier, Katharine A.
AU - Zynger, Debra
AU - Meza, Luis
AU - Beuselinck, Benoit
AU - Agarwal, Neeraj
AU - Mortazavi, Amir
AU - Pal, Sumanta
AU - McKay, Rana
AU - Lam, Elaine T.
AU - Rajaram, Satwik
AU - Brugarolas, James
N1 - Publisher Copyright:
© 2026, Xu et al.
PY - 2026
Y1 - 2026
N2 - BACKGROUND. Clear cell renal cell carcinoma (ccRCC) with pancreatic metastases (PM) is paradoxically associated with prolonged overall survival (OS), but the biological basis for this observation remains unclear. METHODS. We analyzed matched primary and metastatic samples from an international consortium of patients with PM (n = 108) and compared them with a previously characterized ccRCC cohort without PM (n = 273). RESULTS. Primary ccRCC tumors associated with PM were dominated by indolent, angiogenic phenotypes, characterized by low-grade histology and reduced mTORC1 activation (all P < 0.001). Tumors of patients with PM were often PBRM1-deficient (80.4% vs. 54.8%, P < 0.001) and rarely harbored BAP1 loss (3.7% vs. 20.7%, P < 0.001). After metastasis diagnosis, patients with PM had significantly longer median OS compared with those without PM (110 vs. 33 months, HR 0.28 [95% CI, 0.19–0.39], P < 0.001). Survival was further prolonged among patients with PBRM1 loss (143 vs. 64 months, HR 0.41 [95% CI, 0.22–0.81], P = 0.008). Notably, PM lesions were typically low-grade and PBRM1-deficient even when more aggressive and evolved clones were present in primary tumors. Finally, PBRM1 loss was associated with preferential response to angiogenesis inhibitors over immune-oncology therapy, reflected by longer time on treatment (32.1 vs. 9.1 months, HR 0.16 [95% CI, 0.06–0.39], P < 0.001). CONCLUSION. These findings illustrate selective tropism of indolent, less-evolved, PBRM1-deficient ccRCC clones for pancreatic dissemination. This biological bias likely underlies therapeutic sensitivity and favorable survival, supporting the consideration of PBRM1 status and metastatic tropism in risk stratification and treatment selection.
AB - BACKGROUND. Clear cell renal cell carcinoma (ccRCC) with pancreatic metastases (PM) is paradoxically associated with prolonged overall survival (OS), but the biological basis for this observation remains unclear. METHODS. We analyzed matched primary and metastatic samples from an international consortium of patients with PM (n = 108) and compared them with a previously characterized ccRCC cohort without PM (n = 273). RESULTS. Primary ccRCC tumors associated with PM were dominated by indolent, angiogenic phenotypes, characterized by low-grade histology and reduced mTORC1 activation (all P < 0.001). Tumors of patients with PM were often PBRM1-deficient (80.4% vs. 54.8%, P < 0.001) and rarely harbored BAP1 loss (3.7% vs. 20.7%, P < 0.001). After metastasis diagnosis, patients with PM had significantly longer median OS compared with those without PM (110 vs. 33 months, HR 0.28 [95% CI, 0.19–0.39], P < 0.001). Survival was further prolonged among patients with PBRM1 loss (143 vs. 64 months, HR 0.41 [95% CI, 0.22–0.81], P = 0.008). Notably, PM lesions were typically low-grade and PBRM1-deficient even when more aggressive and evolved clones were present in primary tumors. Finally, PBRM1 loss was associated with preferential response to angiogenesis inhibitors over immune-oncology therapy, reflected by longer time on treatment (32.1 vs. 9.1 months, HR 0.16 [95% CI, 0.06–0.39], P < 0.001). CONCLUSION. These findings illustrate selective tropism of indolent, less-evolved, PBRM1-deficient ccRCC clones for pancreatic dissemination. This biological bias likely underlies therapeutic sensitivity and favorable survival, supporting the consideration of PBRM1 status and metastatic tropism in risk stratification and treatment selection.
UR - https://www.scopus.com/pages/publications/105032719690
U2 - 10.1172/JCI.INSIGHT.195195
DO - 10.1172/JCI.INSIGHT.195195
M3 - Article
C2 - 41797716
AN - SCOPUS:105032719690
SN - 2379-3708
VL - 11
SP - 1
EP - 21
JO - JCI Insight
JF - JCI Insight
IS - 5
M1 - e195195
ER -